NEW PATENTS ISSUED IN U.S. AND EUROPE FOR TECHNOLOGY USED IN CORGENIX NEXT GENERATION PREDICTIVE CARDIOVASCULAR DIAGNOSTIC PRODUCT LINE
DENVER, Jan. 20 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has received notification of two new patents for technology to which Corgenix holds exclusive worldwide licensing rights outside of Japan. The technology is incorporated in the company's AtherOx(R) product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease.
US Patent # 7,455,976 was issued November 25, 2008. The patent Method of Measuring Oxidized LDL/B2-Glycoprotein I Complex Occurring in the Living Body is a method patent that incorporates newer immunochemical characteristics for the interaction between oxLDL and B2GPI to form oxLDL/B2GPI (AtherOx complexes) and their use as a standard for more accurate measuring of this complex in biological samples such as serum or plasma.
European patent # EP 1 548-436 B1 was issued November 19, 2008. The patent is also a method patent providing additional European protection to the components and assay procedure used to measure AtherOx complexes in biological samples.
The latest patents add to previous US patents (# 5,900,359 issued May 4, 1999, Method for Determination of Oxidized Lipoproteins and Use Thereof; # 7,160,733 issued January 9, 2007, Ligand Specific to B2-glycoprotein I and Use Thereof; and # 7,422,864 issued September 9, 2008, Method for Measuring Oxidized LDL-CRP Complex and Measurement Kit.) These patents described the specific interaction of B2-glycoprotein I with the oxidized form of low-density lipoprotein (oxLDL) leading to the formation of oxLDL/B2-glycoprotein I complexes (AtherOx). This interaction does not occur with the native or non-oxi
|SOURCE Corgenix Medical Corporation|
Copyright©2009 PR Newswire.
All rights reserved